Market Overview

Illumina Gets Order Worth $17M Over Next Five Years


Illumina, Inc. (NASDAQ: ILMN) today announced it was awarded a contract from the U.S. Food and Drug Administration (FDA) to provide the agency with MiSeq sequencing systems and reagents for conducting whole genome analysis on produce and produce-related environmental Salmonella and shigatoxigenic E. coli isolates. The contract is worth up to $17 million over a period of five years.

Posted-In: News FDA


Related Articles (ILMN)

View Comments and Join the Discussion!

Partner Center